Trial Profile

A Phase 4, Open-label, Study to Investigate the Efficacy and Safety of VTAMA® (Tapinarof) Cream 1% in the Treatment of Plaque Psoriasis in Intertriginous Areas

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Oct 2023 According to a Dermavant Sciences media release, On May 24, 2022, Dermavant announced that the FDA approved VTAMA (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults.
20 Oct 2023 According to a Dermavant Sciences media release, Howard Sofen is the principal investigator of the study.
20 Oct 2023 According to a Dermavant Sciences media release, data from the study were presented at the 43rd Annual Fall Clinical Dermatology Conference, being held in Las Vegas, NV between October 19-22, 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com